Is A Beat In The Cards For Mallinckrodt (MNK) Q1 Earnings?
Zacks Investment Research | May 01, 2019 06:07AM ET
Mallinckrodt plc (NYSE:MNK) is scheduled to report first-quarter results on May 7, before the market opens.
The company’s has surpassed expectations in the last four quarters by an average positive earnings surprise of 16.8%. Let’s see how things are shaping up for this announcement.
Why a Likely Positive Surprise?
Our proven model indicates that Mallinckrodt is likely to beat on earnings this quarter, as it has the right combination of two key ingredients — a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) — to be able to beat estimates.
Earnings ESP: Earnings ESP for Mallinckrodt is +0.25%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter .
Zacks Rank: Mallinckrodt currently carries a Zacks Rank #3, which when combined with a positive ESP makes us confident of an earnings beat.
Note, we caution against Sell-rated stocks (Zacks Rank #4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Factors Impacting Q1
The company now operates in two segments aligned with the previously-announced separation — the Specialty Brands, and the Specialty Generics (includes Amitiza).
Specialty Brands produces and markets branded pharmaceutical products like Acthar, Inomax and Ofirmev, among others.
Sales of Acthar, Mallinckrodt’s largest product, were dented by the residual impact of the previously-reported patient withdrawal issues. We expect softness in the sales of the drug in the first quarter.
Strong performance of Mallinckrodt’s hospital franchise (Inomax and Ofirmev) is expected to continue in the first quarter. Growth in Inomax sales is driven by strong demand and contract renewals. Ofirmev sales are expected to be driven by strong demand, as customers focus on non-opioid or multimodal pain management.
We also expect the company to throw more light on its business separation plan. In December 2018, the company announced that it intends to spin-off the Specialty Generics/Active Pharmaceutical Ingredients business along with Amitiza into a new company.
The spin-off will be completed by the second half of 2019 and will result in two separate, publicly-traded companies.
Apart from the regular top and bottom-line numbers, we expect investors to focus on updates on the company’s two late-phase programs on terlipressin and StrataGraft. Patients are being enrolled in the ongoing phase III trial on pipeline candidate, terlipressin, for the treatment of Hepatorenal Syndrome type 1. StrataGraft is a viable, engineered, bilayer human skin substitute, currently under development for severe burns and other complex skin defects.
Get The News You Want
Share Price Performance
Mallinckrodt’s stock has lost 2.2% in the year so far compared with the industry ’s growth of 7.3%.
Other Stocks to Consider
Here are some other healthcare stocks you may want to consider, as our model shows that these too have the right combination of elements to post an earnings beat this quarter.
Gilead Sciences, Inc. (NASDAQ:GILD) has an Earnings ESP of +1.54% and a Zacks Rank #2. The company is scheduled to release first-quarter results on May 2. You can see .
Horizon Pharma (NASDAQ:HZNP) has an Earnings ESP of +25.00% and a Zacks Rank #3. The company is scheduled to release first-quarter results on May 8.
Aduro Biotech, Inc. (NASDAQ:ADRO) has an Earnings ESP of +82.00% and a Zacks Rank of 2.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft (NASDAQ:MSFT) in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.